Core Insights - Gilead Sciences has reached settlement agreements with Lupin, Cipla, and Laurus Labs to resolve patent disputes concerning Biktarvy, an HIV medication [3]. Company Developments - The settlements allow Lupin, Cipla, and Laurus Labs to produce generic versions of Biktarvy, pending approval from the U.S. Food and Drug Administration [4].